Peninsula drug company regroups after failed study in deadly rare disease in kids
A drug from a small, ambitious Peninsula drug developer failed a clinical trial for an invariably fatal childhood genetic disease, but leaders of the company said they will regroup with the FDA to find a way to move the program forward.
Retrotope Inc. said the late-stage study of its drug RT-001 failed to hit its main goal in infantile neuroaxonal dystrophy, or INAD, a rare condition which robs children of motor skills and voluntary muscle control and typically kills them before they turn 10.
But…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Ron Leuty Source Type: news
More News: Brain | Children | Clinical Trials | Genetics | Health Management | Neurology | Rare Diseases | Reflex Sympathetic Dystrophy | Study